Search Results 611-620 of 17842 for Coagulation

1. Pregnancy and atrial fibrillation - Mayo Clinic

   Being pregnant when you have AFib raises the risk of blood clots. Know which blood-thinning medicines are and are not safe during pregnancy.

2. A Trial of ZL-1201 in Subjects with Advanced Cancer - Mayo Clinic

   ... coagulation and clotting disorders), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere ...

3. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients - Mayo Clinic

   Patient may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as ...

4. BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients - Mayo Clinic

   The patient has adequate coagulation: prothrombin time (PT) and an International Normalized Ratio (INR), and partial thromboplastin time (PTT) ≤ 1.5 times ...

5. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation - Mayo Clinic

   ... coagulation. Subjects with a known medical history of PML. MDS substudy only: Subjects with documented AML (≥ 20% bone marrow or peripheral blood blasts) ...

6. A Study to Evaluate HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors - Mayo Clinic

   Adequate coagulation function: International normalized ratio (INR) <1.3 (or <3.0 on anticoagulants) Exclusion Criteria: 1. Any cancer-directed therapy ...

7. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

   Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin [LMWH], or novel oral anticoagulants) must be discontinued and coagulation ...

8. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

   serum creatinine (μmol/L). Meet the following coagulation requirements: For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 × ULN ...

9. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   Adequate coagulation function defined as prothrombin time or international normalized ratio ≤ 1.5 × ULN unless the participant is receiving anticoagulant ...

10. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies - Mayo Clinic

    History of bleeding disorder or predisposing conditions, blood clotting, or clinically significant abnormal results on coagulation profile at Screening, as ...